open access

Vol 75, No 1 (2024)
Original paper
Submitted: 2023-11-05
Accepted: 2023-11-29
Published online: 2024-02-21
Get Citation

MYB/LINC00092 regulatory axis promotes the progression of papillary thyroid carcinoma

Lian Cheng12, Xian Deng12, Yuan Le3
·
Pubmed: 38497387
·
Endokrynol Pol 2024;75(1):27-34.
Affiliations
  1. Department of General Surgery (Thyroid Surgery), Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
  2. Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, China
  3. Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China

open access

Vol 75, No 1 (2024)
Original Paper
Submitted: 2023-11-05
Accepted: 2023-11-29
Published online: 2024-02-21

Abstract

Introduction: Thyroid carcinoma is the most frequent malignancy in different endocrine-related tumours. In this study, we demonstrated a long non-coding RNA LINC00092-associated molecular mechanism in promoting the progression of papillary thyroid carcinoma (PTC).

Material and methods: The expression of LINC00092 was analysed in the The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) patient cohorts and further determined by q-PCR. (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT) assay, and wound healing assay confirmed the function of LINC00092 in migration and proliferation. Q-ChIP validated the transcriptional target. Luciferase reporter assay validated the miRNA-mRNA target.

Results: The analysis in patient cohorts and in PTC TPC-1 cells showed that the expression of LINC00092 was repressed in thyroid carcinoma. In addition, the expression of LINC00092 was negatively associated with the advanced thyroid TNM stages. LINC00092 repressed epithelial-mesenchymal transition (EMT), migration, and proliferation of TPC-1 cells. Interestingly, we identified that MYB, a well-studied tumour promoter, is a transcription factor of LINC00092, thereby the expression of LINC00092 was directly repressed by MYB. Furthermore, miR-4741 was also validated as a direct target of MYB and was induced by MYB. Notably, LINC00092 was repressed by miR-4741 through the direct 3’-untranslational region (3’-UTR) target. Therefore, MYB induced EMT of TPC-1 cells by repressing LINC00092 directly or indirectly via miR-4741.

Conclusions: Our study validated that LINC00092 is a tumour suppressor lncRNA in PTC. MYB directly or indirectly represses LINC00092, which contributes to the PTC progression. MYB, LINC00092, and miR-4741 form a coherent feed forward loop. The axis of MYB-LINC00092 promotes progression of PTC.

Abstract

Introduction: Thyroid carcinoma is the most frequent malignancy in different endocrine-related tumours. In this study, we demonstrated a long non-coding RNA LINC00092-associated molecular mechanism in promoting the progression of papillary thyroid carcinoma (PTC).

Material and methods: The expression of LINC00092 was analysed in the The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) patient cohorts and further determined by q-PCR. (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT) assay, and wound healing assay confirmed the function of LINC00092 in migration and proliferation. Q-ChIP validated the transcriptional target. Luciferase reporter assay validated the miRNA-mRNA target.

Results: The analysis in patient cohorts and in PTC TPC-1 cells showed that the expression of LINC00092 was repressed in thyroid carcinoma. In addition, the expression of LINC00092 was negatively associated with the advanced thyroid TNM stages. LINC00092 repressed epithelial-mesenchymal transition (EMT), migration, and proliferation of TPC-1 cells. Interestingly, we identified that MYB, a well-studied tumour promoter, is a transcription factor of LINC00092, thereby the expression of LINC00092 was directly repressed by MYB. Furthermore, miR-4741 was also validated as a direct target of MYB and was induced by MYB. Notably, LINC00092 was repressed by miR-4741 through the direct 3’-untranslational region (3’-UTR) target. Therefore, MYB induced EMT of TPC-1 cells by repressing LINC00092 directly or indirectly via miR-4741.

Conclusions: Our study validated that LINC00092 is a tumour suppressor lncRNA in PTC. MYB directly or indirectly represses LINC00092, which contributes to the PTC progression. MYB, LINC00092, and miR-4741 form a coherent feed forward loop. The axis of MYB-LINC00092 promotes progression of PTC.

Get Citation

Keywords

papillary thyroid carcinoma; LINC00092; MYB; miR-4741

About this article
Title

MYB/LINC00092 regulatory axis promotes the progression of papillary thyroid carcinoma

Journal

Endokrynologia Polska

Issue

Vol 75, No 1 (2024)

Article type

Original paper

Pages

27-34

Published online

2024-02-21

Page views

321

Article views/downloads

257

DOI

10.5603/ep.98120

Pubmed

38497387

Bibliographic record

Endokrynol Pol 2024;75(1):27-34.

Keywords

papillary thyroid carcinoma
LINC00092
MYB
miR-4741

Authors

Lian Cheng
Xian Deng
Yuan Le

References (17)
  1. Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery. 2013; 154(6): 1420–6; discussion 1426.
  2. Abdullah MI, Junit SM, Ng KL, et al. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. Int J Med Sci. 2019; 16(3): 450–460.
  3. Karapanou O, Simeakis G, Vlassopoulou B, et al. Advanced RAI-refractory thyroid cancer: an update on treatment perspectives. Endocr Relat Cancer. 2022; 29(5): R57–R66.
  4. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011; 10: 38.
  5. Sui F, Ji M, Hou P. Long non-coding RNAs in thyroid cancer: Biological functions and clinical significance. Mol Cell Endocrinol. 2018; 469: 11–22.
  6. Wang G, Le Y, Wei L, et al. CREB3 Transactivates lncRNA ZFAS1 to Promote Papillary Thyroid Carcinoma Metastasis by Modulating miR-373-3/MMP3 Regulatory Axis. Int J Endocrinol. 2021; 2021: 9981683.
  7. Zhao CM, Li LL, Xu JW, et al. LINC00092 Suppresses the Malignant Progression of Breast Invasive Ductal Carcinoma Through Modulating SFRP1 Expression by Sponging miR-1827. Cell Transplant. 2022; 31: 9636897221086967.
  8. Wang X, Wang X, Huang G, et al. Lower expression of LINC00092 in lung adenocarcinoma might mean poorer prognosis: A study based on data mining and bioinformatics. Medicine (Baltimore). 2020; 99(44): e23012.
  9. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008; 8(7): 523–534.
  10. Thompson MA, Ramsay RG. Myb: an old oncoprotein with new roles. Bioessays. 1995; 17(4): 341–350.
  11. Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol. 2001; 21(17): 5797–5805.
  12. Weston K. Myb proteins in life, death and differentiation. Curr Opin Genet Dev. 1998; 8(1): 76–81.
  13. Jin Y, Qi G, Chen G, et al. Association between B- proto-oncogene and the development of malignant tumors. Oncol Lett. 2021; 21(2): 166.
  14. Zhao L, Ji G, Le X, et al. Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. Cancer Res. 2017; 77(6): 1369–1382.
  15. Huang W, Liu Z, Li Yu, et al. Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma. J Cell Biochem. 2019; 120(3): 4121–4131.
  16. Cicirò Y, Sala A. MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis. 2021; 10(2): 19.
  17. Quintana AM, Liu F, O'Rourke JP, et al. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer. 2011; 11: 30.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl